The pharmaceutical industry is the world’s most aggressive practitioner of intellectual property strategy. Patent thickets, evergreening, paragraph IV litigation, data exclusivity — the sector deploys every available legal instrument to protect the commercial value of its names and molecules. Roche invested $14.43 billion in R&D in 2024 alone. Novartis: $13.7 billion. Sanofi: $7.3 billion. Combined, four European pharma majors — Roche, AstraZeneca, Novartis, and Sanofi — invested $48 billion in a single year in activities that are, at their core, about protecting proprietary names and compounds from competition.
None of them appear to have a Fragment @Name strategy. On Telegram’s official namespace exchange — the platform that has settled over $350 million in username trades since 2022 and now runs on a messaging network with over one billion monthly active users — the brand identities of the world’s largest drug companies sit unclaimed, unprotected, and available to the highest bidder.
Fragment Is Not a Niche Crypto Market Anymore
Fragment, which launched in November 2022 as Telegram’s official username marketplace on the TON blockchain, has moved far beyond its early-adopter phase. The platform’s transaction record demonstrates sustained, escalating market interest. The username @danbao changed hands for $2.2 million in February 2026. @boss — a five-letter English-word handle — was acquired for approximately $64,000 in 2022 and resold in 2025 for 500,000 USDT, an eight-fold return in under three and a half years. The @crypto handle reportedly received an offer of $25 million after its holder acquired it for $350,000. @news sold at launch for approximately $1.7 million.
Each of these sales represents a Telegram username recorded as a non-fungible token on TON blockchain — a form of digital ownership that, by design, cannot be revoked by Telegram itself. Once a name is held as a TON NFT, the only path to recovery is market purchase or legal action against the holder. Neither route is fast or cheap.
Why the Risk Profile Is Uniquely Severe for Pharma
For a consumer brand, an impersonated Telegram handle is a reputational inconvenience. For a pharmaceutical company, it is a patient safety incident waiting to happen.
A Telegram channel operating as @pfizer or @novartis — indistinguishable to a casual user from the legitimate brand — can distribute counterfeit drug information, fake clinical trial announcements, or fraudulent medical guidance to millions of subscribers. In the ASEAN market, where Telegram has between 120 and 140 million users and where counterfeit pharmaceuticals are already a documented problem, the potential for harm is not theoretical. The World Health Organization has consistently flagged digital channels as a primary vector for pharmaceutical fraud in lower-income markets.
The regulatory dimension compounds the risk. A drug company’s FDA or EMA registration does not extend to its Telegram namespace. TON blockchain assets operate outside the jurisdiction of any national pharmaceutical regulator. The company bears reputational liability for communications it did not authorize and cannot stop. Trademark law provides a theoretical remedy, but Fragment’s decentralized structure means no single authority can compel a name transfer — and the legal architecture governing Fragment @Name disputes remains largely untested.
Japan Pharma’s Digital Health Paradox
The exposure is particularly acute among Japan’s leading pharmaceutical companies. Takeda, Astellas, Daiichi Sankyo, Chugai, and Otsuka have each made substantial investments in digital health infrastructure. Astellas has deployed antibody language models in partnership with NVIDIA BioNeMo. Chugai holds PMDA approval for a digital pathology platform. Daiichi Sankyo has cut preclinical timelines through AI-assisted antibody-drug conjugate discovery. These are companies that demonstrably understand the strategic value of digital platforms.
Yet the namespace layer — the one dimension of digital identity that, once lost, cannot be recovered by investment or technology — appears absent from their IP planning. Japan’s pharmaceutical sector operates in a regulatory environment where the PMDA has no authority over blockchain-based assets held by overseas entities. The consequence is a jurisdiction gap that a bad actor can exploit faster than any regulatory response can mobilize. Southeast Asia, where Japanese pharma companies hold significant commercial interests, compounds this: the region’s 120 to 140 million Telegram users represent both a market and a fraud surface.
The Window Is Narrowing
Early Fragment acquisitions in November 2022 were priced in the low thousands of dollars. Four years later, the same class of handles trades in the hundreds of thousands to millions. The market has already repriced the category once; it is repricing again as Telegram’s user base grows and institutional awareness increases.
IP departments that have not added Fragment due diligence to their standard trademark audit cycle are operating on a series of assumptions — that the names are still available, that prices are still negotiable, that no party with adverse intent has noticed. Each assumption erodes daily. For pharmaceutical companies, the adverse-intent scenario is not a speculative brand risk. It is a documented pattern: counterfeit pharmaceutical promotion through impersonated digital channels is an established criminal vector, and Telegram’s scale makes it a primary target.
The Strategic Implication
The pharmaceutical sector has every institutional capacity to act on this exposure. The legal frameworks, IP management workflows, and budget authorization processes all exist. What has been absent is the recognition that Fragment @Names constitute a class of brand asset requiring the same systematic coverage as domain names and social media handles.
A sector that built its commercial model on the premise that names have enforceable value — and that spent a combined $48 billion defending that premise in Europe alone last year — cannot maintain a coherent IP strategy while leaving its Telegram namespace to the open market. The companies that secure their Fragment @Name positions earliest will face the lowest acquisition cost and the highest certainty of control. For the rest, the arithmetic shifts unfavorably with every passing quarter, and the patient safety liability sits unmitigated in the background.